» Articles » PMID: 9270567

Ropinirole for the Treatment of Early Parkinson's Disease. The Ropinirole Study Group

Overview
Journal Neurology
Specialty Neurology
Date 1997 Aug 1
PMID 9270567
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

A prospective, randomized, placebo-controlled, double-blind, parallel-group, 6-month study assessed the efficacy and safety of ropinirole, a nonergoline D2-dopamine agonist, in patients with early Parkinson's disease (n = 241; Hoehn & Yahr stages I to III) with limited or no prior dopaminergic therapy. Patients (mean age, 62.8 years), stratified by concomitant use of selegiline, were randomized to ropinirole (n = 116) or placebo (n = 125). The starting dose of ropinirole was 0.25 mg tid with titration to at least 1.5 mg tid (maximum dose, 8 mg tid). Primary efficacy endpoint was the percentage improvement in Unified Parkinson's Disease Rating Scale (UPDRS) motor score. Ropinirole-treated patients had a significantly greater percentage improvement in UPDRS motor score than patients who received placebo (+24% vs -3%; p < 0.001). Ropinirole was well tolerated and patient withdrawals were infrequent. Most adverse experiences were related to peripheral dopaminergic activity. Ropinirole monotherapy is an effective and well-tolerated therapeutic option for treatment of early Parkinson's disease.

Citing Articles

Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis.

Chen X, Zhang Q, Chen F, Wen S, Zhou C Front Neurol. 2023; 14:1183823.

PMID: 37396766 PMC: 10312085. DOI: 10.3389/fneur.2023.1183823.


Long-term neuropsychological outcomes of deep brain stimulation in early-stage Parkinson's disease.

Hacker M, Tramontana M, Pazira K, Meystedt J, Turchan M, Harper K Parkinsonism Relat Disord. 2023; 113:105479.

PMID: 37380539 PMC: 11232874. DOI: 10.1016/j.parkreldis.2023.105479.


Unraveling pathological mechanisms in neurological disorders: the impact of cell-based and organoid models.

Langlie J, Mittal R, Finberg A, Bencie N, Mittal J, Omidian H Neural Regen Res. 2022; 17(10):2131-2140.

PMID: 35259819 PMC: 9083150. DOI: 10.4103/1673-5374.335836.


The effect and safety of ropinirole in the treatment of Parkinson disease: A systematic review and meta-analysis.

Zhu J, Chen M Medicine (Baltimore). 2021; 100(46):e27653.

PMID: 34797288 PMC: 8601351. DOI: 10.1097/MD.0000000000027653.


In Parkinson's patient-derived dopamine neurons, the triplication of α-synuclein locus induces distinctive firing pattern by impeding D2 receptor autoinhibition.

Lin M, Mackie P, Shaerzadeh F, Gamble-George J, Miller D, Martyniuk C Acta Neuropathol Commun. 2021; 9(1):107.

PMID: 34099060 PMC: 8185945. DOI: 10.1186/s40478-021-01203-9.